Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMV564 in Relapsed/Refractory AML
NCT03144245Phase 1Completed
- Sponsor
- Amphivena Therapeutics
- Start
- Mar 2017
- Primary completion
- Jul 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML) (2 arms), sponsored by Amphivena Therapeutics. Primary endpoints: Incidence of all adverse events and serious adverse events at 42 months and Remission Rate at 42 months. Started Mar 2017; status: completed.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03144245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144245.